The strong interim efficacy data (CR 3x control) is a major catalyst for MBRX, supporting Annamycin's potential in R/R AML. Monitor the 90-patient unblinding in Dec 2026–Feb 2027 for confirmation. The recent dilutive offering at $0.75/share creates overhang, but positive data could drive revaluation if sustained. Cash runway into Q1 2027 requires additional financing for Part B and NDA submission.
Price Chart
Executive Summary
Moleculin Biotech reported Q2 2026 results highlighting positive interim MIRACLE trial data showing complete remission rates three times higher than control (43%/36% vs 12%) in relapsed/refractory AML. The company ended Q2 with $7.3M cash and raised $9.3M post-quarter, extending runway into Q1 2027. Net loss per share improved to -$1.40 from -$28.68 YoY, driven by higher share count and warrant-related gains, but operating losses widened to $7.6M.
Key Financial Metrics
Key Facts
- Interim MIRACLE data: CR 43% (190 mg/m² arm) and 36% (230 mg/m²) vs 12% control; CRc 50% and 57% vs 29% control
- Cash and equivalents $7.3M at June 30, 2026; plus $9.3M raised post-quarter, funding operations into Q1 2027
- Net loss per share -$1.40 (GAAP) vs consensus -$1.55, a 9.7% beat; revenue $0 (pre-revenue)
- Enrollment on track for 90-patient milestone in September 2026; unblinded efficacy readout expected Dec 2026–Feb 2027
- No detectable cardiotoxicity observed; ASCO 2026 data supports differentiated safety profile
Financial Impact
Positive interim MIRACLE data significantly de-risks Annamycin; cash runway extended into Q1 2027 with $9.3M post-quarter raise; recent dilutive offering at $0.75/share creates ~66% discount overhang
Risk Factors
- Recent dilutive offering at $0.75/share (66% discount) increases share count significantly
- Cash runway only into Q1 2027; additional financing needed for Part B and NDA submission
- Clinical risk: 90-patient unblinding may not confirm interim results; regulatory path uncertain
- Pre-revenue with no approved products; stock price highly sensitive to trial outcomes
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001437749-26-027835 |
| Document: mbrx20260811_8k.htm | 0001437749-26-027835 |
| Document: 0001437749-26-027835-index-headers.html | 0001437749-26-027835 |
| Document: 0001437749-26-027835-index.html | 0001437749-26-027835 |
| Document: 0001437749-26-027835.txt | 0001437749-26-027835 |
| 8-K Data (Synthetic) | 0001437749-26-027835 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 20, 2026 6d ago | 8-K | $6.19 | awaiting T+20 | — | $7.09 (+14.46%) |
Oct 16, 2026 10d ago | 8-K | $0.2804 | awaiting T+20 | — | $7.09 (+2426.75%) |
Oct 9, 2026 16d ago | 8-K | $0.4139 | awaiting T+20 | — | $7.09 (+1611.77%) |
Oct 5, 2026 21d ago | 8-K | $0.4766 | awaiting T+20 | — | $7.09 (+1386.57%) |
Sep 29, 2026 27d ago | 8-K | $0.5264 | awaiting T+20 | — | $7.09 (+1245.93%) |
Sep 29, 2026 27d ago | Press Release | $0.5264 | awaiting T+20 | — | $7.09 (+1245.93%) |
Sep 28, 2026 28d ago | 8-K | $0.5690 | awaiting T+20 | — | $7.09 (+1145.17%) |
Sep 25, 2026 4w ago | 8-K | $0.6016 $6.50 | ▲ +980.45% | ▲ +981.93% | $7.09 (+1077.69%) |
Sep 23, 2026 4w ago | 8-K | $0.5279 $6.31 | ▲ +1095.30% | ▲ +1094.61% | $7.09 (+1242.11%) |
Sep 18, 2026 5w ago | 8-K | $0.5202 | awaiting T+20 | — | $7.09 (−1261.98%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers